Minimal Residual Disease (MRD) by Multiparametric Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) in Newly Diagnosed Multiple Myeloma patients: concordance analysis and impact on the outcome of transplant-eligible patients enrolled in the FORTE clinical trial.